Fourteen percent. That's how much rapamycin extended median lifespan in genetically heterogeneous mice at the National Institute on Aging Interventions Testing Program — even when treatment started at the human equivalent of age 60. Three independent sites: Jackson Laboratory, University of Michigan, UT Health Science Center. Multiple cohorts. Same result every time. Then you get to humans — and the data gets very, very complicated.
The Mechanism
mTOR stands for Mechanistic Target of Rapamycin — a serine/threonine kinase that operates as your cell's core growth-versus-repair switch. When rapamycin binds to the intracellular protein FKBP12 and inhibits mTORC1, the cell interprets this as nutrient scarcity. It shifts from growth mode to maintenance mode: autophagy increases, ribosomal protein synthesis slows, and senescence-associated secretory phenotype factors get suppressed.
The complication: there are two mTOR complexes. mTORC1 is the longevity target. mTORC2 regulates insulin signaling through AKT. At higher or chronic doses, rapamycin also inhibits mTORC2 — and that's where the metabolic trade-off lives.
The Evidence For
Strong et al. (NIA ITP, 2016) showed female mice gained 14–20% median lifespan extension, males 10–15%. In humans, the PEARL trial — a double-blind, placebo-controlled RCT of low-dose intermittent rapamycin in healthy normative-aging adults, running 48 weeks — found no serious adverse events attributable to rapamycin (Bitto et al., University of Washington / AgelessRx, Aging, 2025, n=48 weeks). Mannick et al. (Novartis / Brown University, Science Translational Medicine, 2014, n=218) showed the rapalog everolimus improved influenza vaccine response by approximately 20% in adults over 65.
The Evidence Against
Lamming et al. (Whitehead Institute / MIT, Science, 2012) demonstrated directly in mice that chronic rapamycin induced mTORC2 suppression, leading to a diabetic-like metabolic state with insulin resistance — even while extending lifespan. You are trading one hallmark of aging for another. The GWU/Consensus systematic reviews (2025) are unambiguous: no qualifying human RCT demonstrates healthspan extension with rapamycin. Zero qualifying RCTs with validated aging biomarkers and adequate duration in healthy adults were identified across 948 papers screened.
The Verdict
Rapamycin is the most mechanistically credible pharmacological longevity candidate in the peer-reviewed literature. The PEARL trial establishes a short-term safety signal for low-dose intermittent dosing. The optimistic reading: the PEARL intermittent protocol is probably safe. The honest reading: we do not yet know if it works in humans.
Daily Pill — mTOR Fasting Window
Skip breakfast twice a week, targeting a 16-hour overnight fast on those days. A 16-hour fast depletes circulating amino acids and insulin, activating AMPK and suppressing mTORC1 via reduced Rag GTPase activity — without the mTORC2 suppression risk of pharmacological rapamycin. Log your fasting window in Oura or Whoop; check your readiness score and HRV the morning after a fast versus a non-fast baseline; track the delta across four weeks for a personal signal.
